On 14-09-2020 (Monday), Shares of CymaBay Therapeutics, Inc., (NASDAQ: CBAY) displayed a change of 13.3 after which it closed the day’ session at $6.56. The volume amounted to 2635673 shares which compares with the average volume of 3.64M shares. CymaBay Therapeutics, Inc., a USA based Company, belongs to Healthcare sector and Biotechnology industry. The shares of CymaBay Therapeutics, Inc. was among the active stocks of the last trading sessions.
To clear the blur picture shareholders will need to look a little deeper. The LiveRamp Holdings, Inc. has shown a weekly performance of 13.01% and monthly performance stands at 13.79%.
The stock has shown a quarterly performance of 66.92% and a half-year performance stands at 368.57%. Analyst recommendation for this stock stands at 234.69.
The stock price moved with change of 1.0759 to its 50 Day low point and changed -0.0748 comparing to its 50 Day high point.
Looking into the profitability ratios of CBAY stock, the investor will find its ROE, ROA, ROI standing at -43%, -39.6% and 0%, respectively. The current relative strength index (RSI) reading is 60.55.
Target Price CBAY:
Target Price informs the investors, a stock survey at which a trader is willing to buy or sell a stock. Target pricing at which a trader projects that a buyer will buy a product. Analyst’s mean target price for the company is $0.
The stock price volatility remained at 8.23 in recent month and reaches at 9.8 for the week. The Average True Range (ATR) is also a measure of volatility is currently sitting at 0.54.
Simple Moving Averages CBAY:
The moving average is easy to calculate and once plotted on a chart, is a powerful visual trend-spotting tool. In theory, there is an infinite number of simple moving averages but the most common are three SMA20, SMA50 and SMA200. SMA20 is the last stop on the bus for short-term traders. Its distance from 20-days simple moving average is 5.14% and its distance from 50-days simple moving average is 29.89% while it has a distance of 124.13% from the 200-days simple moving average.
Most Important details of CymaBay Therapeutics, Inc. (EPS):
EPS in next five year years is expected to touch 10.4% while EPS growth in past 5 year was 10.4% along with sales growth of % in the last five years. EPS growth in next year is estimated to reach -22.2% while EPS growth estimate for this year is set at -22.2%.